Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance
Phibro reported Q1 net sales of $386.8 million, up 6% year-over-year, with net income of $29.5 million, up 11%, and adjusted diluted EPS of $0.79, up 8%. Management said results exceeded expectations, led by Mineral Nutrition (+17%) and Performance Products (+16%), while core Animal Health grew 3% despite a $5.2 million decline in Brazil virginiamycin sales tied to regulatory delays. The company maintained its FY27 guidance (net sales $1.55B-$1.60B, adjusted EBITDA $258M-$268M); any Brazil regulatory approval for virginiamycin would represent potential upside, as guidance assumes no additional sales there.
Key figures
- Eps
- 0.72
- Revenue
- 386800000
- Guidance
- FY27: net sales $1.55B-$1.60B (4% growth); net income $122M-$132M; diluted EPS $2.98-$3.22; Adjusted EBITDA $258M-$268M (3% growth); adjusted net income $140M-$147M; adjusted diluted EPS $3.41-$3.59 (9% growth); adjusted effective tax rate ~20% — maintained
- Revenue Yoy
- 6%
- Fcf ttm
- 21700000
- Net income
- 29500000
- Total debt
- 739600000
- Adjusted eps
- 0.79
- Gross margin
- 33.2%
- Net income yoy
- 11%
- Adjusted ebitda
- 64300000
- Adjusted eps yoy
- 8%
- Adjusted ebitda yoy
- 4%
- Gross leverage ratio
- 2.9x
- Cash and short term investments
- 83100000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.